AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06264141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide Releasing Solution
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Study NCT06264141 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray with isotonic saline
Description: The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
Study NCT06204692 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: dental implant
Description: consisted of 6 patients where computer guided dental implant placement
Study NCT04881500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Patients will follow motivational interview (2 individual sessions by phone)
Study NCT04881500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Patients will follow routine care
Study NCT05055258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: KVD824 300 mg Modified-Release Tablets
Study NCT05055258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to KVD824
Description: Placebo to KVD824 300 mg Modified-Release Tablets
Study NCT05712304 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: second examination of the proximal colon
Description: For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
Study NCT06404372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demetech Barbed PDO Suture
Description: The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
Study NCT06212505 — intervention group
Intervention type: OTHER
Intervention: blood test
Description: blood test at the inclusion 10 tubes of 2.7mL blood
Study NCT04538274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-driven intervention
Description: Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
Study NCT04657380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN-e-PSY mobile application
Description: The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops
Study NCT04657380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
Study NCT05173688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
Study NCT06542939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated CHW Intervention
Description: Participants will undergo all 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources. There will be two one-on-one virtual meetings, up to 9 follow-up phone calls to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
Study NCT06542939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW Session 1 Only
Description: Participants will attend only the first group-based health education session on hypertension and diabetes management.
Study NCT05912816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 Combined With Tislelizumab
Description: In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour.
Study NCT06040203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)
Description: Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
Study NCT06040203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)
Description: Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
Study NCT06040203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline solution)
Description: Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
Study NCT04999007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence algorithm
Description: Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
Study NCT05971979 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04794972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-039
Description: Administration by intravenous infusion.
Study NCT04975217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT
Study NCT04975217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: Given PO
Study NCT04975217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04975217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care resection
Study NCT04975217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Colonoscopy
Description: Undergo colonoscopy
Study NCT05188066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
Study NCT06566339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotically Aligned Eye Imaging System
Description: Robotically Aligned Eye Imaging System is a non-contact, micrometer scale imaging technique that provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D. The study team will develop hardware systems and software algorithms necessary for acquiring ocular anterior segment images for those seeking eye care in emergency department settings.
Study NCT05866536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin
Description: 2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
Study NCT05866536 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: 2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
Study NCT05136066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with peppermint oil
Description: Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
Study NCT06341959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral screening
Description: The participants in the intervention group will receive an oral examination. Subsequently, information about any identified problem will be given. Lastly, participants will receive a referral letter for their dentist and a report for the general practitioner. If the participants don't have a regular dentist, they will also be given a list with contact information of dentists in the area.
Study NCT05364840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: Orally available protease inhibitor capsule
Study NCT05364840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product capsule
Study NCT06031116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: depigmentation
Description: gingival depigmentation
Study NCT06031116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: depigmentation
Description: gingival depigmentation
Study NCT04415775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game based treadmill Program
Description: Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
Study NCT04415775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Rehabilitation
Description: Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
Study NCT06086067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic session
Description: This session will consist of an aerobic training session performed on a cycle ergometer.
Study NCT05454709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Use of dasiglucagon in the AP system.
Study NCT05454709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen
Description: Use of GlucaGen in the AP system.
Study NCT04945304 — intervention group
Intervention type: PROCEDURE
Intervention: magnetic bariatric surgery
Description: Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
Study NCT04945304 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic gastric bypass
Description: Using the magnetic assistance to perform a gastric bypass
Study NCT05863806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilzation
Description: Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets.
Study NCT04853693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom´s Supporting Mom
Description: A preventive peer consultation intervention for Postpartum Depression.
Study NCT04853693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual
Description: Referral to treatment in the community, clinical monitoring
Study NCT04860895 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AP-23
Description: AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
Study NCT05700994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Contingency Management
Description: Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
Study NCT05863806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trasverse Friction Massage
Description: Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration.
Study NCT05201248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study NCT05068557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).
Description: Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
Study NCT05201248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV Injection
Study NCT05201248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion
Study NCT05201248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV Infusion
Study NCT05201248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV Infusion
Study NCT05201248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet
Study NCT05201248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule
Study NCT05264441 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: In-Check DIAL G16
Description: Patients will inspire into an In-Check DIAL G16 device.
Study NCT05700994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Contingency Management
Description: Participants allocated to standard of care contingency management will receive incentives for peer encounters.
Study NCT04748068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Fr Glidesheath Slender
Description: The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
Study NCT04748068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cordis 7-Fr radial sheath
Description: Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
Study NCT05908370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
Description: Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
Study NCT05036382 — intervention group
Intervention type: BEHAVIORAL
Intervention: Steps data observation
Description: Sending more step data from the experimental group that received the incentive message
Study NCT05472389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video-electroencephalography
Description: All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
Study NCT05472389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Samples
Description: Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children \< 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
Study NCT05079295 — intervention group
Intervention type: PROCEDURE
Intervention: CSDH evacuation
Description: Burr hole for chronic subdural hematomas
Study NCT04741061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sputnik Light
Description: Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose.
Study NCT04741061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05756374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OUT to IN
Description: OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
Study NCT05181423 — intervention group
Intervention type: OTHER
Intervention: Biomarkers
Description: Different serum and radiological biomarkers neonates undergoing abdominal surgery.
Study NCT04857515 — intervention group
Intervention type: DEVICE
Intervention: Clickotine®
Description: Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
Study NCT04814433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given.
Study NCT04814433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Description: FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given.
Study NCT04814433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thrombin
Description: Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given
Study NCT05377918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: spiritual diary group and diary gruop will write a diary